原发性中枢神经系统淋巴瘤分子病理机制的研究进展  

Advances in molecular and pathological mechanism of primary central nervous system lymphoma

作　　者：刘静[1] 王亚明[2] 刘元波[1] 

机构地区：[1]首都医科大学附属北京天坛医院血液科,北京100050 [2]北京海军总医院神经外科

出　　处：《国际输血及血液学杂志》2015年第4期325-329,共5页International Journal of Blood Transfusion and Hematology

基　　金：基金项目：国家自然科学基金资助项目（81272842）

摘　　要：原发性中枢神经系统淋巴瘤（PCNSL）为原发于脑实质、脊髓、眼、脑神经或软脑膜的淋巴瘤。PCNSL与全身系统性淋巴瘤相比，其诊断率低，且治疗效果与预后较差。近年来，随着分子、细胞遗传学检测技术的发展，对PCNSL有了更多认识，其免疫表型、相关基因表达谱对PCNSL的治疗及预后均有重要指导意义。笔者拟就PCNSL组织病理学与分子生物学特征的最新研究进展进行综述。Primary central nervous system lymphoma （PCNSL） refers to lymphomas arising exclusively in the central nervous system, which is the brain parenchyma, spinal cord, eyes, cranial nervous or meninges. Compared with systemic lymphoma, PCNSL is associated with the low diagnostic rate, poor outcome and dismal prognosis. Recent years, intense efforts has made in the development of molecular, cellular genetic testing technology to improve understanding of PCNSL. Immunophenotyping and related gene expression profile have an important guiding significance in the treatment and prognosis of PCNSL. This article reviews literatures to highlight and update concepts regarding the pathology and biological markers of PCNSL.

关 键 词：中枢神经系统 淋巴瘤 免疫表型分型 生物学标记 

分 类 号：R739.4[医药卫生—肿瘤]